Medical authorities report a significant increase in oropharyngeal cancers caused by the human papillomavirus (HPV), with transmission primarily occurring through oral sex. Unlike tobacco-related cancers, these HPV-positive cases often affect younger, healthier individuals and can develop decades after initial exposure.
According to the U.S. Centers for Disease Control and Prevention (CDC), HPV is thought to cause 70% of oropharyngeal cancers in the United States. The high-risk HPV-16 strain is most commonly responsible. Symptoms can include a persistent sore throat, ear pain, difficulty swallowing, or a lump in the neck, often leading to late diagnosis.
"The lag time between infection and cancer can be very long, which is why people are often shocked by the diagnosis," explains an oncologist familiar with the trend. Public health efforts now emphasize that HPV vaccination, recommended for preteens, can prevent these cancers. The vaccine is most effective when administered before exposure to the virus.
Treatment for HPV-positive throat cancer often involves intensive chemotherapy and radiation. Despite the aggressive nature of the disease, studies indicate patients with HPV-positive tumors frequently have better survival rates compared to those with HPV-negative cancers linked to smoking and alcohol.
